Purchase Order 75N93024P01064

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized DNA and monoclonal antibody production, valued at $49,653.58, on August 6, 2020. Performance is located in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 5, 2020.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized monoclonal antibody on June 27, 2018, with a ceiling value of $30,289.88 and firm fixed pricing. Performance is located in Piscataway, New Jersey, with an ultimate completion date of July 10, 2018. No small business set-aside was used.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for antibody gene synthesis and production, valued at $16,974.27, on August 26, 2020. The order was firm fixed price with an ultimate completion date of February 6, 2021. Work was performed at Genscript's facility in Piscataway, New Jersey.</p>

The National Institute of Allergy and Infectious Diseases awarded a $96,595 firm fixed-price purchase order to Genscript USA Inc. on September 20, 2024, for monoclonal antibodies and plasmids services under the FY26 Urgent and Directed Obligation Initiative. The contract is not designated as a set-aside award and carries an ultimate completion date of September 19, 2025. Performance will be conducted at Genscript's facility in Piscataway, New Jersey, where the company maintains its...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $70,395.88 on June 26, 2019, for antibodies (AMBIS #1962008) under firm fixed price, with completion targeted for September 30, 2019. Work is performed in Piscataway, New Jersey. The order originated from a pre-solicitation opportunity posted June 13, 2019, with a due date of June 24, 2019. No small business set-aside applied.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. on January 13, 2021, for development of custom rodent monoclonal antibodies, with a ceiling value of $10,751.45. Performance will occur in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of March 31, 2021.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $249,943.63 on September 16, 2019. The order covers DNA synthesis, plasmid, and protein production services. Work is performed in Piscataway, New Jersey. The purchase order is firm fixed price with an ultimate completion date of January 31, 2020. The order originated from a pre-solicitation opportunity posted September 11, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $1,147,346.00 on September 26, 2019, for customized biologicals under firm fixed pricing. Performance is located in Piscataway, New Jersey. The order has no small business set-aside and carried an ultimate completion date of September 25, 2020. The originating pre-solicitation was posted September 3, 2019, with a due date of September 6, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $11,179.50 on November 18, 2019, for customized gene production, gene synthesis, and cloning services.</p> <p>Place of performance is Piscataway, New Jersey. The order carries a firm fixed price and ultimate completion date of December 6, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $15,028.93 on September 10, 2015, for mutagenesis, gene synthesis, custom plasmid preparation, and reagents. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and no set-aside designation. Ultimate completion is September 13, 2016.</p>